Eight inherited neurological disorders have been found to associate with an expansion of a glutamine repeat in the protein products of the disease genes. Increasing evidence has shown that the expanded glutamine repeat causes the disease proteins to aggregate in the nucleus and to abnormally interact with other proteins, Studies of brains from patients with Huntington's disease (HD) and HD animal models have indicated that N- terminal fragments of huntingtin with expanded polyglutamine accumulate in the nucleus and are toxic to neurons. However, the mechanisms of these pathological events remain unknown.
The aim of this proposal is to investigate the mechanisms of cellular pathology caused by intranuclear huntingtin with expanded polyglutamine. We will use cellular and animal models to address two important questions: (1) how N-terminal fragments of huntingtin with expanded polyglutamine are accumulated in the nucleus, and (2) how intranuclear mutant huntingtin induces cellular dysfunction. Accordingly, two specific aims will be pursued.
Aim 1 is to study how N- terminal huntingtin with expanded polyglutamine is generated and accumulates in the neuronal nucleus and to identify proteins or cellular factors that keep mutant huntingtin in the nucleus.
Aim 2 is to investigate how mutant huntingtin may interact with transcription factors and affects gene transcription. These studies will advance our knowledge about the pathogenesis of HD and provide vital information to help develop therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS041669-03
Application #
6639777
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Oliver, Eugene J
Project Start
2001-05-01
Project End
2005-04-30
Budget Start
2003-05-01
Budget End
2004-04-30
Support Year
3
Fiscal Year
2003
Total Cost
$304,000
Indirect Cost
Name
Emory University
Department
Genetics
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Yan, Sen; Tu, Zhuchi; Li, Shihua et al. (2018) Use of CRISPR/Cas9 to model brain diseases. Prog Neuropsychopharmacol Biol Psychiatry 81:488-492
Guo, Jifeng; Cui, Yiting; Liu, Qiong et al. (2018) Piperine ameliorates SCA17 neuropathology by reducing ER stress. Mol Neurodegener 13:4
Yan, Sen; Tu, Zhuchi; Liu, Zhaoming et al. (2018) A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington's Disease. Cell 173:989-1002.e13
Tu, Zhuchi; Yang, Weili; Yan, Sen et al. (2017) Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos. Sci Rep 7:42081
Wang, Guohao; Liu, Xudong; Gaertig, Marta A et al. (2016) Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A 113:3359-64
Liu, Xudong; Wang, Chuan-En; Hong, Yan et al. (2016) N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy. PLoS Genet 12:e1006083
Yang, Weili; Tu, Zhuchi; Sun, Qiang et al. (2016) CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases. Front Mol Neurosci 9:30
Zhao, Ting; Hong, Yan; Li, Shihua et al. (2016) Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes. J Neurosci 36:8317-28
Yang, Su; Li, Xiao-Jiang; Li, Shihua (2016) Molecular mechanisms underlying Spinocerebellar Ataxia 17 (SCA17) pathogenesis. Rare Dis 4:e1223580
Chen, Yongchang; Zheng, Yinghui; Kang, Yu et al. (2015) Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum Mol Genet 24:3764-74

Showing the most recent 10 out of 64 publications